Drugs / CT-2584
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00004026 | Dec 1998 → Jan 2005 | prostate cancer | CTI BioPharma | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-2584 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004026 ↗ |
| Modality | Small molecule | — CHEMBL4297274 ↗ |
| Route | Intravenous | “Patients receive CT-2584 IV over 6 hours daily for 3 days every 3 weeks.” NCT00004026 ↗ |